The popularity of copyright’s blockbuster initially fueled a boom for the drug industry, but recent shifts present a complicated outlook for shareholders. Off-patent alternatives are reducing earnings, and continued https://tedhudy145450.newbigblog.com/48086140/the-blue-pill-and-big-pharma-a-volatile-bet